Bristol takes aim at three more hep C niches with Daklinza

In the face of hefty hep C competition from Gilead ($GILD) and AbbVie ($ABBV), can Daklinza profit from a set of niche uses? That's what maker Bristol-Myers Squibb ($BMY) is trying to find out. On Tuesday, the med nabbed the FDA's priority review tag for a trio of new indications in hard-to-treat patients. Regulators will examine the med for use with Gilead's Sovaldi in those who are coinfected with HIV-1, suffering from advanced cirrhosis, or experiencing recurrence of hep C after a liver transplant, the company said. More from FiercePharmaMarketing

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.